PTK2 (Human) Cell-Based ELISA Kit

Total Page:16

File Type:pdf, Size:1020Kb

PTK2 (Human) Cell-Based ELISA Kit PTK2 (Human) Cell-Based ELISA Kit Catalog # : KA2852 規格 : [ 1 Kit ] List All Specification Application Image Product PTK2 (Human) Cell-Based ELISA Kit is an indirect enzyme-linked Qualitative Description: immunoassay for qualitative determination of PTK2 expression in cultured cells. Reactivity: Human, Mouse, Rat Storage Store the kit at 4°C. Instruction: Protocol: Protocol Download Suitable Attached Cell, Loosely Attached Cell, Suspension Cell Sample: Label: HRP-conjugated Detection Colorimetric Method: Regulation For research use only (RUO) Status: Applications Qualitative Gene Information Entrez GeneID: 5747 Protein Q05397 Accession#: Gene Name: PTK2 Gene Alias: FADK,FAK,FAK1,pp125FAK Gene PTK2 protein tyrosine kinase 2 Description: Omim ID: 600758 Gene Ontology: Hyperlink Gene Summary: This gene encodes a cytoplasmic protein tyrosine kinase which is found concentrated in the focal adhesions that form between cells growing in the presence of extracellular matrix constituents. The encoded protein is a member of the FAK subfamily of protein tyrosine kinases but lacks significant sequence similarity to kinases from other subfamilies. Activation of this gene may be an important early step in cell growth and intracellular signal transduction pathways triggered in response to certain neural peptides or to cell interactions with the extracellular Page 1 of 2 2017/2/16 matrix. At least four transcript variants encoding four different isoforms have been found for this gene, but the full-length natures of only two of them have been determined. [provided by RefSeq Other focal adhesion kinase 1 Designations: Interactome Gene Pathway Axon guidance Chemokine signaling pathway ErbB signaling pathway Focal adhesion Leukocyte transendothelial migration Pathways in cancer Regulation of actin cytoskeleton Small cell lung cancer VEGF signaling pathway Related Disease Autistic Disorder Genetic Predisposition to Disease HIV Infections Leukemia, chronic myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive Mental Retardation Neovascularization, Pathologic Psychotic Disorders Schizophrenia 服務條款 | 隱私權政策 | 著作及商標 | 網站地圖 ©2017 亞諾法生技股份有限公司 Abnova Corporation. 版權所有. Page 2 of 2 2017/2/16.
Recommended publications
  • Human RET Kinase Protein (His Tag)
    Human RET Kinase Protein (His Tag) Catalog Number: 11997-H08H1 General Information SDS-PAGE: Gene Name Synonym: CDHF12; CDHR16; HSCR1; MEN2A; MEN2B; MTC1; PTC; RET-ELE1; RET51 Protein Construction: A DNA sequence encoding the extracellular domain of human RET (P07949-1) (Met 1-Arg 635) was fused with a polyhistidine tag at the N- terminus. Source: Human Expression Host: HEK293 Cells QC Testing Purity: > 92 % as determined by SDS-PAGE Protein Description Endotoxin: RET proto-oncogene, also known as RET, is a cell-surface molecule that < 1.0 EU per μg of the protein as determined by the LAL method transduce signals for cell growth and differentiation. It contains 1 cadherin domain and 1 protein kinase domain. RET proto-oncogene belongs to the Stability: protein kinase superfamily, tyr protein kinase family. RET proto-oncogene is involved in numerous cellular mechanisms including cell proliferation, ℃ Samples are stable for up to twelve months from date of receipt at -70 neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. It phosphorylates Leu 29 Predicted N terminal: PTK2/FAK1 and regulates both cell death/survival balance and positional Molecular Mass: information. RET is required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric The recombinant human RET consists of 618 amino acids and has a nervous system and renal organogenesis during embryonic life; promotes calculated molecular mass of 69.1 kDa. The apparent molecular mass of the formation of Peyer's patch-like structures; modulates cell adhesion via the protein is approximately 110-120 kDa in SDS-PAGE under reducing its cleavage; involved in the development of the neural crest.
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • 2025.Full-Text.Pdf
    Human Cancer Biology Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-PositiveLeukemiaCellstotheABLKinaseInhibitorSTI571 Noriko Koyama,1Steffen Koschmieder,1SandhyaTyagi,1Ignacio Portero-Robles,1Jo« rg Chromic,1 Silke Myloch,1Heike Nu« rnberger,1Ta nja Ro s s m a ni t h , 1Wolf-Karsten Hofmann,2 Dieter Hoelzer,1and Oliver Gerhard Ottmann1 Abstract Protein tyrosine phosphatase 1B(PTP1B) is a negative regulator of BCR-ABL-mediated transfor- mation in vitro and in vivo. Toinvestigate whether PTP1B modulates the biological effects of the abl kinase inhibitor STI571in BCR-ABL-positive cells, we transfected Philadelphia chromosome ^ positive (Ph+) chronic myeloid leukemia cell-derived K562 cells with either wild-type PTP1B (K562/PTP1B), a substrate-trapping dominant-negative mutant PTP1B(K562/D181A), or empty vector (K562/mock). Cells were cultured with or without STI571and analyzed for its effects on proliferation, differentiation, and apoptosis. In both K562/mock and K562/PTP1B cells, 0.25 to 1 Amol/L STI571 induced dose-dependent growth arrest and apoptosis, as measured by a decrease of cell proliferation and an increase of Annexin V-positive cells and/or of cells in the sub-G1 apoptotic phase. Western blot analysis showed increased protein levels of activated caspase-3 and caspase-8 and induction of poly(ADP-ribose) polymerase cleavage. Low con- centrations of STI571promoted erythroid differentiation of these cells. Conversely, K562/D181A cells displayed significantly lower PTP1B-specific tyrosine phosphatase activity and were signifi- cantly less sensitive to STI571-induced growth arrest, apoptosis, and erythroid differentiation. Pharmacologic inhibition of PTP1B activity in wild-type K562 cells, using bis(N,N-dimethylhy- droxamido)hydroxooxovanadate, attenuated STI571-induced apoptosis.
    [Show full text]
  • Insulin Receptor Substrates-5 and -6 Are Poor Substrates for the Insulin Receptor
    MOLECULAR MEDICINE REPORTS 3: 189-193, 2010 189 Insulin receptor substrates-5 and -6 are poor substrates for the insulin receptor SoETkIn VERSTEyHE1, CHRISToPHE BlanqUart2,3, CoRnElIa HamPE2,3, SHaUkaT maHmooD1, nEVEna CHRISTEFF2,3, PIERRE DE MEYTS1, STEVEn G. GRay1,4 and TARIK ISSAD2,3 1Receptor Systems Biology laboratory, Hagedorn Research Institute, novo nordisk a/S, 2820 Gentofte, Denmark; 2Institut Cochin, Université Paris Descartes, CnRS (UmR 8104), 75014 Paris; 3Inserm, U567, 75654 Paris, France; 4Translational Cancer Research Group, Trinity Centre for Health Sciences, Institute of molecular medicine, St James's Hospital, Dublin 8, Ireland Received September 30, 2009; accepted november 13, 2009 DoI: 10.3892/mmr_00000239 Abstract. Insulin receptor substrates (IRS)-5 and -6 are two leads to the activation of receptor tyrosine kinase and receptor recently identified members of the IRS family. We investi- phosphorylation, which enables the binding of docking proteins gated their roles as insulin receptor substrates and compared such as insulin receptor substrates (IRS)-1, -2, -3 and -4 and them with Src-homology-2-containing (Shc) protein, a Src-homology-2-containing protein (Shc). This in turn leads to well-established substrate. Bioluminescence resonance their phosphorylation and, thereby, intracellular signalling (1). energy transfer (BRET) experiments showed no interaction Until recently, the IRS family included IRS-1, -2, -3 and between the receptor and IRS-5, while interaction with IRS-6 -4 (2) and three downstream of kinases, Dok-1, -2 and -3. was not enhanced by insulin. By contrast, Shc showed an These seven proteins have similar amino-terminal pleckstrin insulin-induced BRET response, as did a truncated form of homology (PH) and similar phosphotyrosine binding (PTB) IRS-1 (1-262).
    [Show full text]
  • Insulin Activates the Insulin Receptor to Downregulate the PTEN Tumour Suppressor
    Oncogene (2014) 33, 3878–3885 OPEN & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc ORIGINAL ARTICLE Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor J Liu1, S Visser-Grieve2,4, J Boudreau1, B Yeung2,SLo1, G Chamberlain1,FYu1, T Sun3,5, T Papanicolaou1, A Lam1, X Yang2 and I Chin-Sang1 Insulin and insulin-like growth factor-1 signaling have fundamental roles in energy metabolism, growth and development. Recent research suggests hyperactive insulin receptor (IR) and hyperinsulinemia are cancer risk factors. However, the mechanisms that account for the link between the hyperactive insulin signaling and cancer risk are not well understood. Here we show that an insulin-like signaling inhibits the DAF-18/(phosphatase and tensin homolog) PTEN tumour suppressor in Caenorhabditis elegans and that this regulation is conserved in human breast cancer cells. We show that inhibiting the IR increases PTEN protein levels, while increasing insulin signaling decreases PTEN protein levels. Our results show that the kinase region of IRb subunit physically binds to PTEN and phosphorylates on Y27 and Y174. Our genetic results also show that DAF-2/IR negatively regulates DAF-18/PTEN during C. elegans axon guidance. As PTEN is an important tumour suppressor, our results therefore suggest a possible mechanism for increased cancer risk observed in hyperinsulinemia and hyperactive IR individuals. Oncogene (2014) 33, 3878–3885; doi:10.1038/onc.2013.347; published online 2 September 2013 Keywords: PTEN; C. elegans; tumour suppressor; cancer; insulin signaling; genetics INTRODUCTION tumour suppression and further substantiate the importance of Insulin and insulin-like growth factor (IGF)-1 signaling are the PTEN regulation in cancer progression.
    [Show full text]
  • Real-Time Quantification of BCR-ABL Mrna Transcripts Using the Lightcycler-T(9;22) Quantification Kit
    real-time-quantification 09.05.2000 19:18 Uhr Seite 8 Real-time Quantification of BCR-ABL mRNA Transcripts Using the LightCycler-t(9;22) Quantification Kit Heiko Wittor 1, Hermann Leying 1, Andreas Hochhaus 2, and Rob van Miltenburg 1 1 Roche Molecular Biochemicals, Penzberg, Germany 2 III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany ly different starting concentrations, so that the initial Introduction target concentration can be determined in a single PCR. The concentration of BCR-ABL transcripts is determi- Literature indicates that in 95 % of all subjects with ned relative to the number of transcripts of a control chronic myeloid leukemia (CML) and in 25-30 % of gene, glucose-6-phosphate dehydrogenase (G6PDH). subjects with acute lymphoblastic leukemia (ALL) a The entire procedure from sample preparation to reciprocal translocation between the long arms of quantitative result is performed in 4.5 hours. chromosome 9 and chromosome 22 [t(9;22)] can be found. This translocation or the resulting fusion pro- duct can be detected by a number of techniques, CLER including fluorescent in situ hybridization, Southern CY blotting, western blotting and reverse transcriptase TThe LightCycler System polymerase chain reaction (RT-PCR). Of these techni- The LightCycler System is based on the amplification LIGHT ques, RT-PCR for the chimeric fusion transcript BCR- of target sequences using alternating heated and ABL has received most attention in relation to the ambient temperature cycles. Samples are contained in detection of minimal residual disease because of its glass capillaries with high surface-to-volume ratio, high sensitivity (1).
    [Show full text]
  • RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
    G C A T T A C G G C A T genes Review RET Gene Fusions in Malignancies of the Thyroid and Other Tissues Massimo Santoro 1,*, Marialuisa Moccia 1, Giorgia Federico 1 and Francesca Carlomagno 1,2 1 Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, 80131 Naples, Italy; lisa.moccia@hotmail.it (M.M.); giorgia.federico@libero.it (G.F.); francesca.carlomagno@unina.it (F.C.) 2 Institute of Endocrinology and Experimental Oncology of the CNR, 80131 Naples, Italy * Correspondence: massimo.santoro@unina.it Received: 10 March 2020; Accepted: 12 April 2020; Published: 15 April 2020 Abstract: Following the identification of the BCR-ABL1 (Breakpoint Cluster Region-ABelson murine Leukemia) fusion in chronic myelogenous leukemia, gene fusions generating chimeric oncoproteins have been recognized as common genomic structural variations in human malignancies. This is, in particular, a frequent mechanism in the oncogenic conversion of protein kinases. Gene fusion was the first mechanism identified for the oncogenic activation of the receptor tyrosine kinase RET (REarranged during Transfection), initially discovered in papillary thyroid carcinoma (PTC). More recently, the advent of highly sensitive massive parallel (next generation sequencing, NGS) sequencing of tumor DNA or cell-free (cfDNA) circulating tumor DNA, allowed for the detection of RET fusions in many other solid and hematopoietic malignancies. This review summarizes the role of RET fusions in the pathogenesis of human cancer. Keywords: kinase; tyrosine kinase inhibitor; targeted therapy; thyroid cancer 1. The RET Receptor RET (REarranged during Transfection) was initially isolated as a rearranged oncoprotein upon the transfection of a human lymphoma DNA [1].
    [Show full text]
  • Inhibition of Syk Protein Tyrosine Kinase Induces Apoptosis and Blocks Proliferation in T-Cell Non-Hodgkin’S Lymphoma Cell Lines
    Letters to the Editor 229 Figure 1 (a–d) The BCR–ABL variants show similar tyrosine phosphorylation profiles in vitro.(a) Domain organization of the three BCR–ABL variants tested in this study. The coiled-coil (CC), DBL and pleckstrin homology (PH) domains pertain to BCR; the SH3, SH2 and TK domains pertain to ABL. The p200BCR–ABL variant lacks the PH domain, while p190BCR–ABL lacks both the PH and DBL-like domains. Each BCR–ABL variant was stably expressed in 32D cells and whole-cell lysates were subjected to immunoblot analysis with antibodies specific for (b) ABL or (c) global tyrosine phosphorylation (4G10). (d) Immunoblot analysis of STAT5 and STAT6 phosphorylation in whole cell lysates from Ba/F3 cells expressing each of the three BCR–ABL variants. (e–h) Deletion of the PH domain is sufficient to increase the lymphoid transformation potency of BCR–ABL. Donor bone marrow cells from (e) 5-FU-treated Balb/c mice or (f) non-5-FU-treated Balb/c mice were infected with equivalent titer retrovirus expressing p210BCR–ABL, p200BCR–ABL or p190BCR–ABL and transplanted into lethally irradiated recipient mice. Kaplan–Meier survival curves are shown. Mortality events due to CML-like disease, B-ALL-like disease and unrelated causes are marked with square, circle and triangle symbols, respectively. (g, h) Representative fluorescence-activated cell sorting analyzes for CML-like and B-ALL-like disease, respectively. Peripheral blood cells were measured for GFP expression on the y axis. The x axis represents staining with antibodies specific for myeloid cells (Ly6G), B cells (B220), T cells (Thy1.2), early myeloid cells (CD11b) or erythroid cells (Ter119).
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential As a Therapeutic Target
    cancers Review Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target Frank Aboubakar Nana 1,2 , Marie Vanderputten 1 and Sebahat Ocak 1,3,* 1 Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL et Dermatologie (PNEU), Université catholique de Louvain (UCLouvain), 1200 Brussels, Belgium; frank.aboubakar@uclouvain.be (F.A.N.); marie.vanderputten@uclouvain.be (M.V.) 2 Division of Pneumology, Cliniques Universitaires St-Luc, UCL, 1200 Brussels, Belgium 3 Division of Pneumology, CHU UCL Namur (Godinne Site), UCL, 5530 Yvoir, Belgium * Correspondence: sebahat.ocak@uclouvain.be; Tel.: +32-2-764-9448; Fax: +32-2-764-9440 Received: 15 September 2019; Accepted: 24 October 2019; Published: 29 October 2019 Abstract: Small-cell lung cancer (SCLC) represents 15% of all lung cancers and it is clinically the most aggressive type, being characterized by a tendency for early metastasis, with two-thirds of the patients diagnosed with an extensive stage (ES) disease and a five-year overall survival (OS) as low as 5%. There are still no effective targeted therapies in SCLC despite improved understanding of the molecular steps leading to SCLC development and progression these last years. After four decades, the only modest improvement in OS of patients suffering from ES-SCLC has recently been shown in a trial combining atezolizumab, an anti-PD-L1 immune checkpoint inhibitor, with carboplatin and etoposide, chemotherapy agents. This highlights the need to pursue research efforts in this field. Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that is overexpressed and activated in several cancers, including SCLC, and contributing to cancer progression and metastasis through its important role in cell proliferation, survival, adhesion, spreading, migration, and invasion.
    [Show full text]
  • Ipsogen® BCR-ABL1 Mbcr Kit Handbook
    July 2016 ipsogen® BCR-ABL1 Mbcr IS-MMR Kit Handbook 24 Version 1 Quantitative in vitro diagnostics For use with Rotor-Gene® Q, Applied Biosystems®, ABI PRISM®, and LightCycler® instruments 670723 QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, GERMANY R3 1072509EN Sample & Assay Technologies QIAGEN Sample and Assay Technologies QIAGEN is the leading provider of innovative sample and assay technologies, enabling the isolation and detection of contents of any biological sample. Our advanced, high-quality products and services ensure success from sample to result. QIAGEN sets standards in: Purification of DNA, RNA, and proteins Nucleic acid and protein assays microRNA research and RNAi Automation of sample and assay technologies Our mission is to enable you to achieve outstanding success and breakthroughs. For more information, visit www.qiagen.com. Contents Intended Use 5 Summary and Explanation 5 Background on CML 5 Disease monitoring 5 Principle of the Procedure 7 Materials Provided 9 Kit contents 9 Materials Required but Not Provided 10 Warnings and Precautions 11 General precautions 11 Reagent Storage and Handling 12 Specimen Handling and Storage 12 Procedure 13 Sample RNA preparation 13 Protocols Reverse transcription using SuperScript III Reverse Transcriptase 13 qPCR on Rotor Gene Q MDx 5plex HRM or Rotor-Gene Q 5plex HRM instruments with 72-tube rotor 16 qPCR on Applied Biosystems 7500 Real-Time PCR System, ABI PRISM 7900HT SDS, and LightCycler 480 instruments 20 qPCR on LightCycler 1.2, 1.5, and 2.0 Instruments 26 Interpretation
    [Show full text]
  • Targeting ALK: Precision Medicine Takes on Drug Resistance
    Published OnlineFirst January 25, 2017; DOI: 10.1158/2159-8290.CD-16-1123 REVIEW Targeting ALK: Precision Medicine Takes on Drug Resistance Jessica J. Lin 1 , Gregory J. Riely 2 , and Alice T. Shaw 1 ABSTRACT Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK - rearranged malignancies, including non–small cell lung cancer. However, the clinical benefi t of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discov- ered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK. Signifi cance: Effective long-term treatment of ALK -rearranged cancers requires a mechanistic under- standing of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabili- ties within a patient’s tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and poten- tially prevent, these resistance mechanisms will have the greatest impact on patient outcome. Cancer Discov; 7(2); 137–55. ©2017 AACR. INTRODUCTION trials demonstrating remarkable responses in this patient population ( 3–8 ). Yet, as with any targeted therapy, tumor The discovery of anaplastic lymphoma kinase ( ALK ) dates cells evolve and invariably acquire resistance to ALK TKIs, back to 1994 when a chromosomal rearrangement t(2;5), leading to clinical relapse.
    [Show full text]